Table 5.5.
Small interfering RNA (siRNA) drugs in development
Drug | Route | Company | Clinical trial phase | ClinicalTrials.gov identifier |
---|---|---|---|---|
VIR-2218 (ALN-HBV02) | Parenteral (SC) | Alnylam and Vir Biotech, USA | 2 | NCT03672188 |
JNJ-3989 (ARO-HBV) | Parenteral (SC) | Arrowhead Pharma with Janssen, USA | 2a | NCT03365947 |
RG6346 (DCR HBVS) | Parenteral (SC) | Roche, Switzerland | 2/1 | NCT03772249 |
AB-729 [57] | Parenteral (SC) | Arbutus Biopharma, USA | 1 | NA |
NA not available